Position in ZYME
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$114,029,348
-$6,971,423 QoQ
Shares Held
4,553,888
-0.9% QoQ
Ownership
6.24%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 95%
Shared 0%
None 5%
Common Shares in ZYME Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026BlackRock, Inc. holds $71,871,411,786 across 472 Biotechnology names. ZYME ranks #102 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
23,969,517 | $10,703,348,112 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
8,947,735 | $6,913,377,962 | |
| 3 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
10,444,908 | $3,455,906,700 | |
| 4 | INSM |
INSMED Inc
|
16,678,146 | $2,727,210,424 | |
| 5 | INCY |
Incyte Corp
|
18,978,198 | $1,786,227,985 | |
| 6 | MRNA |
Moderna, Inc.
|
29,635,876 | $1,505,502,491 | |
| 7 | EXEL |
Exelixis, Inc.
|
30,816,309 | $1,321,711,486 | |
| 8 | RPRX |
Royalty Pharma plc
|
25,907,745 | $1,242,794,517 |
All Filings in ZYME
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $114,029,348 | 4,553,888 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $121,000,771 | 4,595,548 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $68,141,217 | 3,989,533 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $47,618,108 | 3,794,272 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $48,705,000 | 4,089,421 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $61,267,751 | 4,184,956 | Shares | Sole | 2025-02-07 | |
| 2024-09-30 | $53,508,112 | 4,263,595 | Shares | Sole | 2024-11-13 | |
| No filing history on record for this holder in this stock. | ||||||